REGULATORY
AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
The Japan Agency for Medical Research and Development (AMED) and the Japan Pharmaceutical Manufacturers Association (JPMA) appear to be continuing their behind-the-scenes discussions on joint drug discovery research using company compounds. Makoto Suematsu, president of AMED, suggested as much in…
To read the full story
REGULATORY
- US Opens Probe into German Drug Pricing Policies; Could Japan Be Next?
June 24, 2026
- Japan Awards Sakigake Tag to AbbVie’s Bispecific Etentamig
June 24, 2026
- Japan Grants Orphan Status to Vanda, Quoin Drugs, and Lots More
June 24, 2026
- Carvykti Earlier Use Up for Japan Panel Review on June 29
June 23, 2026
- Kampo Industry Calls for Predictable Drug Pricing to Support Stable Supply
June 23, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





